ASH 2020 | Accelerated venetoclax ramp-up for R/R CLL
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, outlines a multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Venetoclax treatment in patients with CLL poses a risk of tumor lysis syndrome (TLS), which is effectively mitigated by the FDA approved five-week ramp-up. However, this long ramp-up period may lead to clinical deterioration while patients are receiving lower doses. This study found that although accelerated venetoclax ramp-up increases the risk of TLS, it may be feasible at experienced academic centers with close inpatient monitoring. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Matthew Davids, MD, has participated in scientific advisory boards, has done consultancy work or has received honoraria from AbbVie, Adaptive Biosciences, Ascentage Pharma, AstraZeneca, BeiGene, Celgene, Eli Lilly, Genentech, Janssen, MEI Pharma, Merck, Novartis, Pharmacyclics, TG Therapeutics, Verastem and Research to Practice; and has received research funding from Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics and Verastem.
